{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:57:07Z","timestamp":1772780227058,"version":"3.50.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,9,14]],"date-time":"2014-09-14T00:00:00Z","timestamp":1410652800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s11926-014-0454-3","type":"journal-article","created":{"date-parts":[[2014,9,13]],"date-time":"2014-09-13T08:19:32Z","timestamp":1410596372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Judicious Use of Biologicals in Juvenile Idiopathic Arthritis"],"prefix":"10.1007","volume":"16","author":[{"given":"Yongdong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,14]]},"reference":[{"key":"454_CR1","first-page":"1520","volume":"29","author":"PJ Manners","year":"2002","unstructured":"Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol. 2002;29:1520\u201330.","journal-title":"J Rheumatol"},{"key":"454_CR2","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/1529-0131(199909)42:9<1843::AID-ANR8>3.0.CO;2-M","volume":"42","author":"KJ Murray","year":"1999","unstructured":"Murray KJ, Moroldo MB, Donnelly P, Prahalad S, Passo MH, Giannini EH, et al. Age-specific effects of juvenile rheumatoid arthritis-associated HLA alleles. Arthritis Rheum. 1999;42:1843\u201353.","journal-title":"Arthritis Rheum"},{"key":"454_CR3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/ard.45.6.464","volume":"45","author":"PJ Hall","year":"1986","unstructured":"Hall PJ, Burman SJ, Laurent MR, Briggs DC, Venning HE, Leak AM, et al. Genetic susceptibility to early onset pauciarticular juvenile chronic arthritis: a study of HLA and complement markers in 158 British patients. Ann Rheum Dis. 1986;45:464\u201374.","journal-title":"Ann Rheum Dis"},{"key":"454_CR4","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/1529-0131(199809)41:9<1620::AID-ART12>3.0.CO;2-L","volume":"41","author":"MB Moroldo","year":"1998","unstructured":"Moroldo MB, Donnelly P, Saunders J, Glass DN, Giannini EH. Transmission disequilibrium as a test of linkage and association between HLA alleles and pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 1998;41:1620\u20134.","journal-title":"Arthritis Rheum"},{"key":"454_CR5","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/art.10337","volume":"46","author":"A Smerdel","year":"2002","unstructured":"Smerdel A, Lie BA, Ploski R, Koeleman BPC, F\u00f8rre \u00d8, Thorsby E, et al. A gene in the telomeric HLA complex distinct from HLA-A is involved in predisposition to juvenile idiopathic arthritis. Arthritis Rheum. 2002;46:1614\u20139.","journal-title":"Arthritis Rheum"},{"key":"454_CR6","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/rheumatology\/41.10.1183","volume":"41","author":"W Thomson","year":"2002","unstructured":"Thomson W, Barrett JH, Donn R, Pepper L, Kennedy LJ, Ollier WER, et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology (Oxford). 2002;41:1183\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"454_CR7","first-page":"1166","volume":"22","author":"T Mason","year":"1995","unstructured":"Mason T, Rabinovich CE, Fredrickson DD, Amoroso K, Reed AM, Stein LD, et al. Breast feeding and the development of juvenile rheumatoid arthritis. J Rheumatol. 1995;22:1166\u201370.","journal-title":"J Rheumatol"},{"key":"454_CR8","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/ije\/dyi006","volume":"34","author":"JJK Jaakkola","year":"2005","unstructured":"Jaakkola JJK, Gissler M. Maternal smoking in pregnancy as a determinant of rheumatoid arthritis and other inflammatory polyarthropathies during the first 7 years of life. Int J Epidemiol. 2005;34:664\u201371.","journal-title":"Int J Epidemiol"},{"key":"454_CR9","first-page":"72","volume":"64","author":"DJ Lovell","year":"2006","unstructured":"Lovell DJ. Update on treatment of arthritis in children: new treatments, new goals. Bull NYU Hosp Jt Dis. 2006;64:72\u20136.","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"454_CR10","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/annrheumdis-2012-201620","volume":"72","author":"JS Smolen","year":"2013","unstructured":"Smolen JS, van der Heijde DM, Keystone EC, van Vollenhoven RF, Goldring MB, Gu\u00e9rette B, et al. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Ann Rheum Dis. 2013;72:1156\u201362.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"454_CR11","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3899\/jrheum.131503","volume":"41","author":"CA Wallace","year":"2014","unstructured":"Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O\u2019Neil KM, Zeft AS, et al. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol. 2014;41(6):1163\u201370. doi: 10.3899\/jrheum.131503 .","journal-title":"J Rheumatol"},{"key":"454_CR12","first-page":"386","volume":"30","author":"B Flat\u00f8","year":"2003","unstructured":"Flat\u00f8 B, Lien G, Smerdel A, Vinje O, Dale K, Johnston V, et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol. 2003;30:386\u201393.","journal-title":"J Rheumatol"},{"key":"454_CR13","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810\u201320.","journal-title":"N Engl J Med"},{"key":"454_CR14","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/art.22709","volume":"56","author":"RK Saurenmann","year":"2007","unstructured":"Saurenmann RK, Rose JB, Tyrrell P, Feldman BM, Laxer RM, Schneider R, et al. Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum. 2007;56:1974\u201384.","journal-title":"Arthritis Rheum"},{"key":"454_CR15","first-page":"1989","volume":"29","author":"K Oen","year":"2002","unstructured":"Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol. 2002;29:1989\u201399.","journal-title":"J Rheumatol"},{"key":"454_CR16","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1001\/jama.294.13.1671","volume":"294","author":"PJ Hashkes","year":"2005","unstructured":"Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005;294:1671\u201384.","journal-title":"JAMA"},{"key":"454_CR17","first-page":"832","volume":"30","author":"K Oen","year":"2003","unstructured":"Oen K, Reed M, Malleson PN, Cabral DA, Petty RE, Rosenberg AM, et al. Radiologic outcome and its relationship to functional disability in juvenile rheumatoid arthritis. J Rheumatol. 2003;30:832\u201340.","journal-title":"J Rheumatol"},{"key":"454_CR18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763\u20139.","journal-title":"N Engl J Med"},{"key":"454_CR19","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096\u2013106.","journal-title":"Arthritis Rheum"},{"key":"454_CR20","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","volume":"58","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin S-L, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58:1496\u2013504.","journal-title":"Arthritis Rheum"},{"key":"454_CR21","first-page":"585","volume":"30","author":"K Oen","year":"2003","unstructured":"Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Reed M, et al. Early predictors of longterm outcome in patients with juvenile rheumatoid arthritis: subset-specific correlations. J Rheumatol. 2003;30:585\u201393.","journal-title":"J Rheumatol"},{"key":"454_CR22","author":"J Guzman","year":"2014","unstructured":"Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis. 2014. doi: 10.1136\/annrheumdis-2014-205372 .","journal-title":"Ann Rheum Dis"},{"key":"454_CR23","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","volume":"70","author":"P Tynj\u00e4l\u00e4","year":"2011","unstructured":"Tynj\u00e4l\u00e4 P, V\u00e4h\u00e4salo P, Tarkiainen M, Kr\u00f6ger L, Aalto K, Malin M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70:1605\u201312. This is the first study using ACR Pediatric 75 as a primary outcome in polyarticular JIA. Efficacies of different treatments, including a combination of infliximab and methotrexate, were compared in a very early phase of JIA with median onset less than 2 months.","journal-title":"Ann Rheum Dis"},{"key":"454_CR24","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","volume":"64","author":"CA Wallace","year":"2012","unstructured":"Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, Neil KMO, Zeft AS, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:2012\u201321. This is the first randomized control trial on polyarticular JIA using clinically inactive disease at 6 months as a primary outcome. ACR Pediatric 70 response at 4 months was proposed as a predictor of clinically inactive disease at 6 months.","journal-title":"Arthritis Rheum"},{"key":"454_CR25","first-page":"366","volume":"25","author":"B Flat\u00f8","year":"1998","unstructured":"Flat\u00f8 B, Aasland A, Vinje O, F\u00f8rre O. Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J Rheumatol. 1998;25:366\u201375.","journal-title":"J Rheumatol"},{"key":"454_CR26","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1002\/art.10444","volume":"46","author":"K Minden","year":"2002","unstructured":"Minden K, Niewerth M, Listing J, Biedermann T, Bollow M, Sch\u00f6ntube M, et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2002;46:2392\u2013401.","journal-title":"Arthritis Rheum"},{"key":"454_CR27","first-page":"2256","volume":"27","author":"K Minden","year":"2000","unstructured":"Minden K, Kiessling U, Listing J, Niewerth M, D\u00f6ring E, Meincke J, et al. Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol. 2000;27:2256\u201363.","journal-title":"J Rheumatol"},{"key":"454_CR28","first-page":"469","volume":"19","author":"I Olivieri","year":"1992","unstructured":"Olivieri I, Foto M, Ruju GP, Gemignani G, Giustarini S, Pasero G. Low frequency of axial involvement in Caucasian pediatric patients with seronegative enthesopathy and arthropathy syndrome after 5 years of disease. J Rheumatol. 1992;19:469\u201375.","journal-title":"J Rheumatol"},{"key":"454_CR29","first-page":"192","volume":"16","author":"R Burgos-Vargas","year":"1989","unstructured":"Burgos-Vargas R, Clark P. Axial involvement in the seronegative enthesopathy and arthropathy syndrome and its progression to ankylosing spondylitis. J Rheumatol. 1989;16:192\u20137.","journal-title":"J Rheumatol"},{"key":"454_CR30","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1002\/art.22181","volume":"54","author":"B Flat\u00f8","year":"2006","unstructured":"Flat\u00f8 B, Hoffmann-Vold A-M, Reiff A, F\u00f8rre \u00d8, Lien G, Vinje O. Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study. Arthritis Rheum. 2006;54:3573\u201382.","journal-title":"Arthritis Rheum"},{"key":"454_CR31","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.3899\/jrheum.110145","volume":"38","author":"MH Otten","year":"2011","unstructured":"Otten MH, Prince FHM, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, et al. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010. J Rheumatol. 2011;38:2258\u201363.","journal-title":"J Rheumatol"},{"key":"454_CR32","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","volume":"73","author":"G Horneff","year":"2014","unstructured":"Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014;73:1114\u201322. First clinical trial of biological treatment for extended oligoarticular JIA, psoriatic JIA, and ERA.","journal-title":"Ann Rheum Dis"},{"key":"454_CR33","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3899\/jrheum.110427","volume":"38","author":"K Donnithorne","year":"2011","unstructured":"Donnithorne K, Cron RQ, Beukelman T. Attainment of inactive disease status following initiation of TNF-\u03b1 inhibitor therapy in a heterogeneous cohort of children with juvenile idiopathic arthritis: enthesitis related arthritis predicts persistent active disease. J Rheumatol. 2011;38:2675\u201381.","journal-title":"J Rheumatol"},{"key":"454_CR34","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, Chao C-C, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t(+) CD3(+)CD4(\u2212)CD8(\u2212) entheseal resident T cells. Nat Med. 2012;18:1069\u201376.","journal-title":"Nat Med"},{"key":"454_CR35","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","volume":"73","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy D, Hermann K-G, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73:817\u201323. This is the first clinical trial of anti-IL12\/23 biological treatment of ankylosing spondylitis.","journal-title":"Ann Rheum Dis"},{"key":"454_CR36","first-page":"491","volume":"27","author":"C Lomater","year":"2000","unstructured":"Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000;27:491\u20136.","journal-title":"J Rheumatol"},{"key":"454_CR37","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/art.21774","volume":"54","author":"D Singh-Grewal","year":"2006","unstructured":"Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006;54:1595\u2013601.","journal-title":"Arthritis Rheum"},{"key":"454_CR38","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FHM, Zeft A, Rabinovich CE, van Rossum MAJ, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63:545\u201355. The largest retrospective cohort study assessing efficacy of anakinra for systemic JIA.","journal-title":"Arthritis Rheum"},{"key":"454_CR39","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol (Hoboken, NJ). 2014;66:1034\u201343. First report of efficacy of anakinra for steroid-na\u00efve systemic JIA patients. ACR Pediatric 90 at 3 months was used as stop strategy for anakinra.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"454_CR40","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396\u2013406. Pioneering randomized double-blinded clinical trial of canakinumab for systemic JIA.","journal-title":"N Engl J Med"},{"key":"454_CR41","author":"NT Ilowite","year":"2014","unstructured":"Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, et al. The RAndomized Placebo Phase Study Of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT). Arthritis Rheum. 2014. doi: 10.1002\/art.38699 . Pioneering randomized double-blinded clinical trial of rilonacept for systemic JIA.","journal-title":"Arthritis Rheum"},{"key":"454_CR42","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F Benedetti De","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385\u201395. Pioneering randomized double-blinded clinical trial of tocilizumab for systemic JIA.","journal-title":"N Engl J Med"},{"key":"454_CR43","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","volume":"64","author":"EM DeWitt","year":"2012","unstructured":"DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2012;64:1001\u201310. Clinical consensus from the largest pediatric rheumatology organization on treatment plan for systemic JIA.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"454_CR44","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/art.38615","volume":"66","author":"PA Nigrovic","year":"2014","unstructured":"Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol (Hoboken, NJ). 2014;66:1405\u201313. A thorough review of mechanism, treatment, and potential window of opportunity for early biological treatment of systemic JIA.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"454_CR45","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998\u20131006.","journal-title":"Lancet"},{"key":"454_CR46","first-page":"1133","volume":"34","author":"EM Behrens","year":"2007","unstructured":"Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34:1133\u20138.","journal-title":"J Rheumatol"},{"key":"454_CR47","first-page":"21","volume":"47","author":"SI Kuzmanova","year":"2005","unstructured":"Kuzmanova SI. The macrophage activation syndrome: a new entity, a potentially fatal complication of rheumatic disorders. Folia Med (Plovdiv). 2005;47:21\u20135.","journal-title":"Folia Med (Plovdiv)"},{"key":"454_CR48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/RHU.0b013e318205092d","volume":"17","author":"N Bruck","year":"2011","unstructured":"Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol. 2011;17:23\u20137.","journal-title":"J Clin Rheumatol"},{"key":"454_CR49","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/ncprheum0919","volume":"4","author":"A Kelly","year":"2008","unstructured":"Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008;4:615\u201320.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"454_CR50","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.22087","volume":"65","author":"S Ringold","year":"2013","unstructured":"Ringold S, Weiss PF, Beukelman T, Dewitt EM, Ilowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among c. Arthritis Care Res (Hoboken). 2013;65:1551\u201363. ACR guideline for treatment of JIA, with particular focus on systemic JIA and its complication, macrophage-activation syndrome.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"454_CR51","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63:465\u201382. ACR guideline for treatment of JIA, derived from rigorous evidence review and expert panel review.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"454_CR52","doi-asserted-by":"crossref","unstructured":"Smith JA, Mackensen F, Sen HN, Leigh JF, Watkins AS, Pyatetsky D, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology. 2009;116:1544\u201351. 1551.e1. doi: 10.1016\/j.ophtha.2009.05.002 . Erratum in: Ophthalmology. 2011;118(8):1494.","DOI":"10.1016\/j.ophtha.2009.05.002"},{"key":"454_CR53","doi-asserted-by":"crossref","unstructured":"Holland GN, Denove CS, Yu F. Chronic anterior uveitis in children: clinical characteristics and complications. Am J Ophthalmol. 2009;147:667\u2013678.e5.","DOI":"10.1016\/j.ajo.2008.11.009"},{"key":"454_CR54","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaapos.2008.03.007","volume":"12","author":"K Sabri","year":"2008","unstructured":"Sabri K, Saurenmann RK, Silverman ED, Levin AV. Course, complications, and outcome of juvenile arthritis-related uveitis. J AAPOS Am Assoc Pediatr Ophthalmol Strabismus. 2008;12:539\u201345.","journal-title":"J AAPOS Am Assoc Pediatr Ophthalmol Strabismus"},{"key":"454_CR55","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0161-6420(97)30329-7","volume":"104","author":"MR Dana","year":"1997","unstructured":"Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology. 1997;104:236\u201344.","journal-title":"Ophthalmology"},{"key":"454_CR56","first-page":"2031","volume":"24","author":"EC Chalom","year":"1997","unstructured":"Chalom EC, Goldsmith DP, Koehler MA, Bittar B, Rose CD, Ostrov BE, et al. Prevalence and outcome of uveitis in a regional cohort of patients with juvenile rheumatoid arthritis. J Rheumatol. 1997;24:2031\u20134.","journal-title":"J Rheumatol"},{"key":"454_CR57","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0161-6420(01)00773-4","volume":"108","author":"K Kotaniemi","year":"2001","unstructured":"Kotaniemi K, Kautiainen H, Karma A, Aho K. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology. 2001;108:2071\u20135.","journal-title":"Ophthalmology"},{"key":"454_CR58","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.ophtha.2006.05.016","volume":"113","author":"LI Kump","year":"2006","unstructured":"Kump LI, Casta\u00f1eda RAC, Androudi SN, Reed GF, Foster CS. Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis. Ophthalmology. 2006;113:1874\u20137.","journal-title":"Ophthalmology"},{"key":"454_CR59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/bjo.86.1.51","volume":"86","author":"C Edelsten","year":"2002","unstructured":"Edelsten C, Lee V, Bentley CR, Kanski JJ, Graham EM. An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol. 2002;86:51\u20136.","journal-title":"Br J Ophthalmol"},{"key":"454_CR60","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jpeds.2006.04.058","volume":"149","author":"LB Vazquez-Cobian","year":"2006","unstructured":"Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149:572\u20135.","journal-title":"J Pediatr"},{"key":"454_CR61","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/rheumatology\/kem356","volume":"47","author":"P Tynj\u00e4l\u00e4","year":"2008","unstructured":"Tynj\u00e4l\u00e4 P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47:339\u201344.","journal-title":"Rheumatology (Oxford)"},{"key":"454_CR62","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jaapos.2008.08.007","volume":"12","author":"I Tugal-Tutkun","year":"2008","unstructured":"Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N. Retrospective analysis of children with uveitis treated with infliximab. J AAPOS Am Assoc Pediatr Ophthalmol Strabismus. 2008;12:611\u20133.","journal-title":"J AAPOS Am Assoc Pediatr Ophthalmol Strabismus"},{"key":"454_CR63","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/rheumatology\/ken298","volume":"47","author":"G Simonini","year":"2008","unstructured":"Simonini G, Zannin ME, Caputo R, Falcini F, de Martino M, Zulian F, et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology (Oxford). 2008;47:1510\u20134.","journal-title":"Rheumatology (Oxford)"},{"key":"454_CR64","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/ard.2006.065441","volume":"66","author":"SM Sharma","year":"2007","unstructured":"Sharma SM, Ramanan AV, Riley P, Dick AD. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis. 2007;66:840\u20131.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"454_CR65","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jpeds.2006.08.044","volume":"149","author":"RK Saurenmann","year":"2006","unstructured":"Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-tnf alpha agents. J Pediatr. 2006;149(6):833\u20136.","journal-title":"J Pediatr"},{"key":"454_CR66","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1002\/art.11155","volume":"48","author":"A Reiff","year":"2003","unstructured":"Reiff A. Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis Rheum. 2003;48:2079\u201380.","journal-title":"Arthritis Rheum"},{"key":"454_CR67","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O","volume":"44","author":"A Reiff","year":"2001","unstructured":"Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001;44:1411\u20135.","journal-title":"Arthritis Rheum"},{"key":"454_CR68","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2005.09.037","volume":"113","author":"RT Rajaraman","year":"2006","unstructured":"Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113:308\u201314.","journal-title":"Ophthalmology"},{"key":"454_CR69","doi-asserted-by":"crossref","unstructured":"Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113:860\u20134.e2.","DOI":"10.1016\/j.ophtha.2006.01.005"},{"key":"454_CR70","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/bjo.2007.124081","volume":"91","author":"M Gallagher","year":"2007","unstructured":"Gallagher M, Quinones K, Cervantes-Casta\u00f1eda RA, Yilmaz T, Foster CS. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol. 2007;91:1341\u20134.","journal-title":"Br J Ophthalmol"},{"key":"454_CR71","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","volume":"91","author":"S Biester","year":"2007","unstructured":"Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319\u201324.","journal-title":"Br J Ophthalmol"},{"key":"454_CR72","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/acr.20115","volume":"62","author":"F Zulian","year":"2010","unstructured":"Zulian F, Balzarin M, Falcini F, Martini G, Alessio M, Cimaz R, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010;62:821\u20135.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"454_CR73","first-page":"1897","volume":"35","author":"S Angeles-han","year":"2008","unstructured":"Angeles-han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis \u2212\u2212 a case report. J Rheumatol. 2008;35:1897\u20138.","journal-title":"J Rheumatol"},{"key":"454_CR74","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00417-010-1523-6","volume":"249","author":"N Kenawy","year":"2011","unstructured":"Kenawy N, Cleary G, Mewar D, Beare N, Chandna A, Pearce I. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249:297\u2013300.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"454_CR75","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol"},{"key":"454_CR76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1546-0096-11-11","volume":"11","author":"Y Butbul Aviel","year":"2013","unstructured":"Butbul Aviel Y, Tyrrell P, Schneider R, Dhillon S, Feldman BM, Laxer R, et al. Juvenile Psoriatic Arthritis (JPsA): juvenile arthritis with psoriasis? Pediatr Rheumatol Online J Pediatric Rheumatol. 2013;11:11.","journal-title":"Pediatr Rheumatol Online J Pediatric Rheumatol"},{"key":"454_CR77","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/annrheumdis-2012-203130","volume":"73","author":"JAB Nies Van","year":"2014","unstructured":"Van Nies JAB, Krabben A, Schoones JW, Huizinga TWJ, Kloppenburg M, van der Helm-van Mil AHM. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73:861\u201370.","journal-title":"Ann Rheum Dis"},{"key":"454_CR78","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","volume":"43","author":"VPK Nell","year":"2004","unstructured":"Nell VPK, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43:906\u201314.","journal-title":"Rheumatology (Oxford)"},{"key":"454_CR79","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/art.30371","volume":"63","author":"C Lukas","year":"2011","unstructured":"Lukas C, Combe B, Ravaud P, Sibilia J, Landew R, van der Heijde D. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the \u00c9tude et Suivi des polyarthrites indiff\u00e9renci\u00e9es r\u00e9centes (study and followup of early undifferentiated polyarthritis). Arthritis Rheum. 2011;63:1804\u201311.","journal-title":"Arthritis Rheum"},{"key":"454_CR80","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1002\/art.27692","volume":"62","author":"MPM Linden Van der","year":"2010","unstructured":"Van der Linden MPM, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TWJ, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62:3537\u201346.","journal-title":"Arthritis Rheum"},{"key":"454_CR81","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/ard.60.10.924","volume":"60","author":"LM Jansen","year":"2001","unstructured":"Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis. 2001;60:924\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"454_CR82","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/acr.22259","volume":"66","author":"S Ringold","year":"2014","unstructured":"Ringold S, Weiss PF, Colbert RA, DeWitt EM, Lee T, Onel K, et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for new onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2014;66(7):1063\u201372. doi: 10.1002\/acr.22259 . Clinical consensus from the largest pediatric rheumatology organization on treatment plan for polyarticular JIA.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"454_CR83","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/rheumatology\/ket465","volume":"53","author":"H Yamanaka","year":"2014","unstructured":"Yamanaka H, Ishiguro N, Takeuchi T, Miyasaka N, Mukai M, Matsubara T, et al. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Rheumatology (Oxford). 2014;53:904\u201313. Clinical trial with the objective of comparing clinical, functional, and radiographic outcomes between early aggressive therapy of adalimumab and methotrexate at treatment onset and addition of adalimumab at 26 weeks.","journal-title":"Rheumatology (Oxford)"},{"key":"454_CR84","first-page":"S14","volume":"31","author":"CF Allaart","year":"2013","unstructured":"Allaart CF, Lems WF, Huizinga TWJ. The BeSt way of withdrawing biologic agents. Clin Exp Rheumatol. 2013;31:S14\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"454_CR85","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.10710","volume":"48","author":"DJ Lovell","year":"2003","unstructured":"Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003;48:218\u201326.","journal-title":"Arthritis Rheum"},{"key":"454_CR86","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/ard.2007.087130","volume":"68","author":"P Tynj\u00e4l\u00e4","year":"2009","unstructured":"Tynj\u00e4l\u00e4 P, V\u00e4h\u00e4salo P, Honkanen V, Lahdenne P. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68:552\u20137.","journal-title":"Ann Rheum Dis"},{"key":"454_CR87","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-P\u00e9rez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372:383\u201391.","journal-title":"Lancet"},{"key":"454_CR88","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10067-011-1720-7","volume":"30","author":"E Alexeeva","year":"2011","unstructured":"Alexeeva E, Valieva S, Bzarova T. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30:1163\u201372.","journal-title":"Clin Rheumatol"},{"key":"454_CR89","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747\u201354.","journal-title":"Ann Rheum Dis"},{"key":"454_CR90","author":"MF Pouw","year":"2013","unstructured":"Pouw MF, Krieckaert CL, Nurmohamed MT, van der Kleij D, Aarden L, Rispens T, et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis. 2013. doi: 10.1136\/annrheumdis-2013-204172 . Important report on relationship between serum adalimumab trough level and clinical response in rheumatoid arthritis.","journal-title":"Ann Rheum Dis"},{"key":"454_CR91","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1136\/annrheumdis-2013-204971","volume":"73","author":"E Ducourau","year":"2014","unstructured":"Ducourau E, Ternant D, Lequerr\u00e9 T, Fuzibet P, Le Lo\u00ebt X, Watier H, et al. Towards an individualised target concentration of adalimumab in rheumatoid arthritis. Ann Rheum Dis. 2014;73:1428\u20139.","journal-title":"Ann Rheum Dis"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-014-0454-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-014-0454-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-014-0454-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T13:20:29Z","timestamp":1717334429000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-014-0454-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,14]]},"references-count":91,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["454"],"URL":"https:\/\/doi.org\/10.1007\/s11926-014-0454-3","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,14]]},"article-number":"454"}}